ImmuneRegen(R) Announces Preliminary Results on Dermatological Testing: Homspera(R)...

ImmuneRegen(R) Announces Preliminary Results on Dermatological Testing: Homspera(R) Accelerates Wound Healing in vivo and Shows Immune Enhancing Activity on Subcutaneous Administration

Company Extends Findings in Support of Licensure for Skin
Applications
SCOTTSDALE, Ariz.--(Business Wire)--
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB:IRBO), today announced that
preliminary results from ongoing studies in dermatological
applications support Management's goals in pursuing licensure for
accelerated wound healing as well as subcutaneous immunomodulation and
vaccine adjuvant activity.

Intra-lesional administration of Homspera was seen to accelerate
the rate of wound closure in porcine full thickness surgical wound
studies. Additional findings regarding time course and pathology of
treated sites will be forthcoming. Based on positive results, and to
better understand the scope and mechanism of Homspera activity,
ImmuneRegen might subsequently pursue additional studies of Homspera
in models of diabetic wounds or burn injury.

The adjuvant findings were part of additional, ongoing studies
designed to further explore the previously announced vaccine adjuvant
effects of Homspera. As an adult stem cell active compound, Homspera
has been shown to impact the bone marrow-derived hematopoietic stem
cell and elevate levels of circulating immune cells. These new
findings show enhanced immune responses to antigen co-administered
subcutaneously with Homspera. This immunomodulatory activity suggests
additional mechanisms may be invoked by Homspera, perhaps including
direct, receptor-mediated stimulation of the antigen-presenting cells
of the immune system. A combination of increased immune cell number
and directly enhancing immune cell activity could underlie Homspera's
effectiveness as a vaccine adjuvant. Additional findings will be
forthcoming.

About ImmuneRegen BioSciences, Inc.

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB:IRBO), is a development-stage
biotechnology company focused on the research, development and
licensing of Homspera(R), an adult stem cell active compound that can
potentially regenerate and strengthen the immune system. To advance
its mission, the Scottsdale, Arizona-based company has forged numerous
study partnerships with industry and academic leaders, including
Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory
Research Institute and Virion Systems. For more information, please
visit www.immuneregen.com.

Statements about ImmuneRegen's future expectations, including
statements about the potential for ImmuneRegen's drug candidates,
science and technology, and all other statements in this press release
other than historical facts, are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934, and as that term is defined in
the Private Securities Litigation Reform Act of 1995. ImmuneRegen
intends that such forward-looking statements be subject to the safe
harbors created thereby. These future events may not occur as and when
expected, if at all, and, together with ImmuneRegen's business, are
subject to various risks and uncertainties. ImmuneRegen's actual
results could differ materially from expected results as a result of a
number of factors, including the fact that preliminary results
involved only a small number of test mice, the subsequent
investigations were limited in scope, the uncertainties inherent in
research and development collaborations, pre-clinical and clinical
trials and product development programs (including, but not limited to
the fact that future results or research and development efforts may
prove less encouraging than current results or cause side effects not
observed in current pre-clinical trials), the evaluation of potential
opportunities, the level of corporate expenditures and monies
available for further studies, capital market conditions, and others
set forth in ImmuneRegen's periodic report on Form 10-Q for the three
months ended March 31, 2008 as filed with the Securities and Exchange
Commission. There are no guarantees that any of ImmuneRegen's proposed
products will prove to be commercially successful. ImmuneRegen
undertakes no duty to update forward-looking statements.

Amendola Communications for ImmuneRegen
Jan Shulman, 480-664-8412, x12
jshulman@ACmarketingPR.com
or
Jodi Amendola, 480-664-8412, x11
jamendola@ACmarketingPR.com

Copyright Business Wire 2008